Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stroke treatment upgrade: adding a Clot-Buster after clot removal may boost recovery

NCT ID NCT07687056

Disease control Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether giving a clot-busting drug directly into the brain arteries after mechanical clot removal can improve recovery in people having a severe stroke. About 1,500 adults with acute ischemic stroke who undergo endovascular thrombectomy will be randomly assigned to receive either the extra drug or standard care alone. The study measures how independent participants are 90 days later, aiming to see if the added treatment reduces long-term disability.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tenecteplase or Alteplase (clot-busting drugs)
What this could lead to
If successful, this approach could become a standard addition to stroke treatment, helping more people recover with less disability after a severe stroke.
What could go wrong
This is a large phase 3 trial, but the added drug may increase bleeding risk in the brain. The benefit may be small or not apply to all stroke patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Mar 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years 2. Clinical diagnosis of stroke Exclusion Criteria: There are no platform level exclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke (AIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke (AIS) Endovascular thrombectomy Stroke, acute ischemic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHUM -Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada

  • CIUSSS de l'Estrie - CHUS Fleurimont Hôpital (Sherbrooke)

    Sherbrooke, Quebec, Canada

  • Health Sciences North Horizon Sante-Nord

    Greater Sudbury, Ontario, Canada

  • Kelowna Regional Hospital

    Kelowna, British Columbia, Canada

  • Ottawa Civic Hospital

    Ottawa, Ontario, Canada

  • Royal Columbian Hospital

    New Westminster, British Columbia, Canada

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada

  • Sunnybrook Health Science Centre

    Toronto, Ontario, Canada

  • The George Institute for Global Health

    Sydney, Barangaroo, NSW 2000, Australia

  • University of Alberta

    Edmonton, Alberta, Canada

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • University of Calgary- Foothills Medical Centre

    Calgary, Alberta, T2N2T9, Canada

  • University of Manitoba - Winnipeg Health Science Centre

    Winnipeg, Manitoba, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.